Open AccessChimeric antigen receptor-T cells immunotherapy for targeting breast cancer
Author(s) -
Ilnaz Rahimmanesh,
Hossein Khanahmad
Publication year - 2021
Publication title -
research in pharmaceutical sciences
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.685
H-Index - 29
eISSN - 1735-9414
pISSN - 1735-5362
DOI - 10.4103/1735-5362.323911
Subject(s) - chimeric antigen receptor , immunotherapy , antigen , breast cancer , cancer research , cancer , medicine , tumor microenvironment , cancer immunotherapy , cancer cell , immunology , major histocompatibility complex , immune system , tumor cells
Redirected chimeric antigen receptor (CAR) T-cells can recognize and eradicate cancer cells in a major histocompatibility complex independent manner. Genetic engineering of T cells through CAR expression has yielded great results in the treatment of hematological malignancies compared with solid tumors. There has been a constant effort to enhance the effectiveness of these living drugs, due to their limited success in targeting solid tumors. Poor T cell trafficking, tumor-specific antigen selection, and the immunosuppressive tumor microenvironment are considered as the main barriers in targeting solid tumors by CAR T-cells. Here, we reviewed the current state of CAR T-cell therapy in breast cancer, as the second cancer-related death in women worldwide, as well as some strategies adopted to keep the main limitations of CAR T-cells under control. Also, we summarized various approaches that have been developed to enhance the therapeutic outcomes of this treatment in solid tumors targeting.